U.S. stock market midday update: Jyong Biotech's stock price plummets 10.17% as expansion into the Vietnamese market fails to gain favor

U.S. Stock Market Midday Update

Jyong Biotech fell 10.17%. Based on recent key news:

1. On December 4, Jyong Biotech announced the signing of a memorandum of understanding with a Vietnamese pharmaceutical distributor, planning to enter the MCS-2 market. This move was interpreted by the market as a strategic expansion of regional cooperation, but failed to boost the stock price, which instead fell 10.17% due to market concerns over risks in the new market. Source: Reuters The pharmaceutical industry has been volatile recently, requiring attention to policy changes.

Stocks with High Trading Volume in the Industry

Praxis Precision Medicines rose 30.81%. Based on recent key news:

1. On December 5, Praxis Precision Medicines announced that its tremor drug ulixacaltamide's new drug application (NDA) has been approved by the U.S. FDA, causing the stock price to rise 36%. The drug has shown significant efficacy for tremor disease, with peak sales expected to exceed $2.5 billion. Source: Reuters

2. On December 5, the company prematurely ended a study on epilepsy due to its significant efficacy, causing the stock price to soar 30%. This unexpected success further boosted market confidence in its epilepsy treatment. Source: CNBC

3. On December 5, Praxis Precision Medicines completed a pre-NDA meeting with the FDA regarding ulixacaltamide, alleviating some regulatory risks. Analysts believe that 2026 could be a transformative year for the company's long-term growth. Source: WSJ The biopharmaceutical industry has performed strongly recently, with noticeable capital inflows.

Amgen fell 2.51%, with increased trading volume. Based on recent key news:

1. On December 4, BMO Capital raised Amgen's target price from $335 to $372, maintaining an "Outperform" rating. This move reflects analysts' continued confidence in the biotechnology group; however, the stock price failed to rise, indicating a lukewarm market response. (Gelonghui)

2. On December 4, Amgen reported third-quarter results that exceeded expectations, primarily due to sales growth of Repatha and strong contributions from Prolia and rare disease drugs, with full-year guidance for 2025 raised. Nevertheless, concerns over increasing drug pricing pressure still affect investor sentiment. (Gelonghui)

3. On December 3, Goldman Sachs reiterated its buy rating on Amgen and maintained a target price of $400, anticipating key updates from the Phase II trial of the obesity drug MariTide. Despite positive trial results, the market remains cautious about the drug's long-term performance. (Gelonghui) The biotechnology industry faces pricing pressures, with reduced capital inflows Precision Science rose by 0.05%, with a transaction volume reaching USD 352 million and an increase in trading volume, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Stocks ranked among the top in industry market capitalization

AbbVie fell by 1.11%. Based on recent key news:

1. On December 5th, AbbVie's immunology business continued to perform strongly after losing patent protection for Humira, primarily driven by Skyrizi and Rinvoq. Sales of these two drugs increased by 53% year-on-year, reaching USD 18.5 billion, and are expected to exceed USD 31 billion by 2027. This growth keeps AbbVie competitive in the immunology market.

2. On December 5th, AbbVie discussed new treatment strategies for platinum-resistant ovarian cancer at the ESMO Asia 2025 conference. Experts highlighted the potential of antibody-drug conjugates (ADCs) in improving efficacy and patient quality of life, which may influence AbbVie's R&D direction.

3. On December 5th, market analysts rated AbbVie as "Moderate Buy," but it was not included in the top recommended stocks list. Analysts believe there are other stocks with greater investment value, which may affect investor confidence in AbbVie. Competition in the immunology market is intensifying, with a focus on R&D investment